© 2022 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#AIDS 2006
Click Here for More Conferences
Click Here for IAS Online
HIV: The Basics

Is Kaletra Monotherapy Possible?

Ten years after combination HIV treatment was heralded as the one and only way to treat HIV, data are emerging to suggest that monotherapyR...

Sustiva vs. Kaletra? We Have a Likely Winner

DHHS currently recommends either Sustiva® or Kaletra® for HIV-positive people starting treatment for the first time.

AIDS 2006 Podcast Coverage

Podcast coverage of the XVI International AIDS Conference in Toronto, Canada, August 13-18, 2006.

IAC: Diary of a Doc (The DART Debate)

There’s always a lot of anticipation about the “late breaker” session, which presents research that wasn’t available until the last mi...

Dr. Martin Markowitz on MK-0518

AIDSmeds Founder Peter Staley interviewed Dr. Martin Markowitz of the Aaron Diamond AIDS Research Center.

Lead Researcher Discusses KLEAN

AIDSmeds Founder Peter Staley interviewed Dr. Joe Eron from the University of North Carolina in Chapel Hill and lead investigator of KLEAN.

Growth Hormone for Lipo

Encouraging results from a second study were reported today.

Dr. Donald Kotler Responds to Critics of FRAM

AIDSmeds Founder Peter Staley interviewed Dr. Donald Kotler, Chief of Gastroenterology at St. Luke’s-Roosevelt Hospital.

IAC: Encouraging TNX-355 Data

Forty-eight week results from a phase II clinical trial of TNX-355, an HIV-entry inhibitor, were reported today at the XVI International AIDS...

Lexiva Measures Up to Kaletra

Final data from a 48-week study comparing Norvir (ritonavir)-boosted Lexiva (fosamprenavir) to Kaletra (ritonavir-boosted lopinavir).

IAC: Data, Access for Integrase Inhibitor

Preliminary results from an ongoing clinical trial of MK-0518, Merck’s experimental integrase inhibitor, suggest that it has comparable anti-H...

Maraviroc Less Effective but Safe for Some

Results from a clinical trial presented at the XVI International AIDS Conference (IAC) indicate that maraviroc, Pfizer’s experimental entry in...

IAC: Vicriviroc Shows Promise

The AIDS Clinical Trials Group has reported results from a clinical trial of vicriviroc, an experimental entry inhibitor being developed by Sc...
Gregg Gonsalves

Activist Gonsalves Slams Gates & Clinton

AIDSmeds Founder Peter Staley interviewed Gregg Gonsalves, former Director of Treatment & Prevention Advocacy at GMHC.

Dr. Anthony Fauci Gets Grilled

AIDSmeds Founder Peter Staley interviewed Dr. Anthony Fauci, Director of NIAID at the NIH, and head of AIDS research for U.S. government.

IAC: Nutritional Boost CD4 Counts

Longtime nutrition advocate Jon Kaiser, MD, and his colleagues presented data at the XVI International AIDS Conference regarding the effects o...
Advertisement
Newsfeed
Science News
Features
Opinions